

Sapna P Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7821939/publications.pdf>

Version: 2024-02-01

90
papers

11,168
citations

126907

33
h-index

69250

77
g-index

97
all docs

97
docs citations

97
times ranked

16816
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
2	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
3	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
4	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
5	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
6	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
7	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
8	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	9.4	283
9	Uveal melanoma: From diagnosis to treatment and the science in between. <i>Cancer</i> , 2016, 122, 2299-2312.	4.1	272
10	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	10.7	233
11	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
12	Long-Term Outcomes in Patients With BRAF V600 Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	1.6	196
13	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	1.2	171
14	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	1.6	156
15	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
16	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
17	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
18	First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6309-6319.	7.0	114

#	ARTICLE	IF	CITATIONS
19	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
20	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	7.0	89
21	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	4.1	78
22	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer, 2013, 119, 799-805.	4.1	63
23	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy†. Annals of Oncology, 2020, 31, 1075-1082.	1.2	62
24	Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Network Open, 2020, 3, e207911.	5.9	59
25	Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. , 2021, 9, e001800.		59
26	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 553-561.	4.2	57
27	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016, 5, e1136044.	4.6	55
28	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
29	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. Cancer Research, 2019, 79, 2838-2838.	0.9	50
30	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology, 2017, 6, e1321187.	4.6	45
31	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open, 2018, 3, e000283.	4.5	45
32	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	1.8	45
33	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 126, 523-530.	4.1	43
34	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895.	7.0	42
35	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	7.1	41
36	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37

#	ARTICLE	IF	CITATIONS
37	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
38	A phase II study of gefitinib in patients with metastatic melanoma. <i>Melanoma Research</i> , 2011, 21, 357-363.	1.2	33
39	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
40	Adjuvant Pembrolizumab versus IFN γ 2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	9.4	32
41	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	1.9	31
42	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 856.	3.7	31
43	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
44	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
45	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	4.2	29
46	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	3.7	27
47	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
48	Latest Developments in the Biology and Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 509-516.	4.0	25
49	Profile of ipilimumab and its role in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2011, 5, 489.	4.3	23
50	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	7.0	23
51	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	1.6	23
52	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
53	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
54	The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). <i>Clinical Cancer Research</i> , 2021, 27, 28-33.	7.0	19

#	ARTICLE	IF	CITATIONS
55	GNAQ mutation in a patient with metastatic mucosal melanoma. <i>BMC Cancer</i> , 2014, 14, 516.	2.6	18
56	Comparative analysis of the <i>GNAQ</i> , <i>GNA11</i> , <i>SF3B1</i> , and <i>EIF1AX</i> driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 470-473.	3.3	18
57	A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2270.	3.7	18
58	Circulating Tumor Cells in Stage IV Melanoma Patients. <i>Journal of the American College of Surgeons</i> , 2018, 227, 116-124.	0.5	17
59	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
60	Surveillance Options for Patients with Uveal Melanoma Following Definitive Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 382-387.	3.8	16
61	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	4.1	15
62	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
63	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652.	1.4	15
64	A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2020, 30, 574-579.	1.2	12
65	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983.	4.1	12
66	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	1.0	11
67	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	4.1	10
68	Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. <i>Frontiers in Oncology</i> , 2022, 12, 806501.	2.8	10
69	GNA11 Mutation in a Patient With Cutaneous Origin Melanoma. <i>Medicine (United States)</i> , 2016, 95, e2336.	1.0	9
70	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD1 in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202.	4.1	9
71	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. <i>Cancer Epidemiology</i> , 2018, 57, 80-84.	1.9	7
72	The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. , 2022, 10, e003533.		7

#	ARTICLE	IF	CITATIONS
73	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	4.1	6
74	Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1132-1136.	1.3	5
75	Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application. <i>Cancer Research</i> , 2018, 78, 614-614.	0.9	5
76	Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. <i>Cancers</i> , 2021, 13, 3292.	3.7	4
77	Immunotherapy for uveal melanoma. <i>Melanoma Management</i> , 2016, 3, 125-135.	0.5	3
78	Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. <i>Cancer Research</i> , 2019, 79, 1493-1493.	0.9	3
79	25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions. <i>Current Oncology Reports</i> , 2022, 24, 533-542.	4.0	3
80	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
81	Leptomeningeal disease in uveal melanoma: a case series. <i>Journal of Neuro-Oncology</i> , 2018, 139, 503-505.	2.9	2
82	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
83	An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. <i>Onc Immunology</i> , 2021, 10, 1984059.	4.6	2
84	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016). <i>Frontiers in Oncology</i> , 2022, 12, 853076.	2.8	2
85	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2018, 40, 831-835.	0.6	1
86	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
87	311...Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma. , 2020, , .		1
88	It's Right, Left is Rare. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1482-1483.	1.3	0
89	Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM). , 2018, , .		0
90	Abstract 3640: Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM). , 2018, , .		0